About this Journal Submit a Manuscript Table of Contents
Scientifica
Volume 2014 (2014), Article ID 765629, 8 pages
http://dx.doi.org/10.1155/2014/765629
Review Article

Therapy of Hypoparathyroidism by Replacement with Parathyroid Hormone

Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 Aarhus, Denmark

Received 15 January 2014; Revised 9 June 2014; Accepted 12 June 2014; Published 1 July 2014

Academic Editor: Gregory Fraley

Copyright © 2014 Lars Rejnmark et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. V. Thakker, “Genetic developments in hypoparathyroidism,” The Lancet, vol. 357, no. 9261, pp. 974–976, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Lima, T. G. Abrahamsen, A. B. Wolff et al., “Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome,” European Journal of Endocrinology, vol. 165, no. 2, pp. 345–352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Al-Azem and A. A. Khan, “Hypoparathyroidism,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 26, no. 4, pp. 517–522, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Underbjerg, T. Sikjaer, L. Mosekilde, and L. Rejnmark, “Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study,” Journal of Bone and Mineral Research, vol. 28, no. 11, pp. 2277–2285, 2013. View at Publisher · View at Google Scholar
  5. B. Clarke, C. L. Leibson, J. Emerson, J. C. Ransom, and H. Lagast, “Co-morbid medical conditions associated with prevalent hypoparathyroidism: a population-based,” Journal of Bone and Mineral Research, vol. 26, supplement 1, 2011, http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=9981fa1f-6bd8-41ec-8b16-9fd94fefd913.
  6. J. Powers, K. Joy, A. Ruscio, and H. Lagast, “Prevalence and incidence of hypoparathyroidism in the United States using a large claims database,” Journal of Bone and Mineral Research, vol. 28, pp. 2570–2576, 2013.
  7. W. Arlt, C. Fremerey, F. Callies et al., “Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D,” European Journal of Endocrinology, vol. 146, no. 2, pp. 215–222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Hadker, J. Egan, J. Sanders, H. Lagast, and B. Clarke, “Understanding the burden of illness associated with hypoparathyroidism reported among patients in the Paradox study,” Endocrine Practice, pp. 1–35, 2014. View at Publisher · View at Google Scholar
  9. S. Aggarwal, S. Kailash, R. Sagar et al., “Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium,” European Journal of Endocrinology, vol. 168, no. 6, pp. 895–903, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Sikjaer, L. Rolighed, A. Hess, A. Fuglsang-Frederiksen, L. Mosekilde, and L. Rejnmark, “Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial,” Osteoporosis International, vol. 25, no. 6, pp. 1717–1726, 2014. View at Publisher · View at Google Scholar
  11. A. G. Bagó, E. Dimitrov, R. Saunders et al., “Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human,” Neuroscience, vol. 162, no. 1, pp. 128–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Tomaschitz, E. Ritz, B. Pieske, et al., “Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease,” Metabolism, vol. 63, pp. 20–31, 2014.
  13. D. M. Mitchell, S. Regan, M. R. Cooley et al., “Long-term follow-up of patients with hypoparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 12, pp. 4507–4514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. B. L. Clarke, J. Kay Berg, J. Fox, J. A. Cyran, and H. Lagast, “Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1–84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study,” Clinical Therapeutics, vol. 36, no. 5, pp. 722–736, 2014. View at Publisher · View at Google Scholar
  15. P. A. Tambyah, B. K. C. Ong, and K. O. Lee, “Reversible parkinsonism and asymptomatic hypocalcemia with basal ganglia calcification from hypoparathyroidism 26 years after thyroid surgery,” The American Journal of Medicine, vol. 94, no. 4, pp. 444–445, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Uncini, A. Tartaro, S. E. Di Stefano, and D. Gambi, “Parkinsonism, basal ganglia calcification and epilepsy as late complications of postoperative hypoparathyroidism,” Journal of Neurology, vol. 232, no. 2, pp. 109–111, 1985. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Sikjaer, L. Rejnmark, L. Rolighed, L. Heickendorff, L. Mosekilde, and The Hypoparathyroid Study Group, “The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study,” Journal of Bone and Mineral Research, vol. 26, no. 10, pp. 2358–2370, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Sikjaer, A. K. Amstrup, L. Rolighed, S. G. Kjaer, L. Mosekilde, and L. Rejnmark, “PTH (1–84) replacement therapy in hypoparathyroidism: a Randomized Controlled Trial on Pharmacokinetic and Dynamic effects following 6 months of treatment,” Journal of Bone and Mineral Research, vol. 28, pp. 2232–2243, 2013.
  19. S. E. Liebman, J. G. Taylor, and D. A. Bushinsky, “Idiopathic hypercalciuria,” Current Rheumatology Reports, vol. 8, no. 1, pp. 70–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Sikjaer, L. Rejnmark, J. S. Thomsen et al., “Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study,” Journal of Bone and Mineral Research, vol. 27, no. 4, pp. 781–788, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Albright and R. Ellsworth, “Studies on the physiology of the parathyroid glands: I. Calcium and Phosphorus Studies on a Case of Idiopathic Hypoparathyroidism,” Journal of Clinical Investigation, vol. 7, pp. 183–201, 1929.
  22. R. A. Melick, J. R. Gill Jr., S. A. Berson et al., “Antibodies and clinical resistance to parathyroid hormone,” The New England Journal of Medicine, vol. 276, no. 3, pp. 144–147, 1967. View at Publisher · View at Google Scholar · View at Scopus
  23. K. K. Winer, N. Sinaii, D. Peterson, B. Sainz Jr., and G. B. Cutler Jr., “Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 9, pp. 3389–3395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. K. Winer, N. Sinaii, J. Reynolds, D. Peterson, K. Dowdy, and G. B. Cutler Jr., “Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2680–2688, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. K. K. Winer, B. Zhang, J. A. Shrader et al., “Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. 391–399, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. K. K. Winer, J. A. Yanovski, B. Sarani, and G. B. Cutler Jr., “A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 10, pp. 3480–3486, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. K. K. Winer, C. W. Ko, J. C. Reynolds et al., “Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 9, pp. 4214–4220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. K. K. Winer, J. A. Yanovski, and G. B. Cutler Jr., “Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism,” Journal of the American Medical Association, vol. 276, no. 8, pp. 631–636, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. M. R. Rubin, D. W. Dempster, J. Sliney Jr. et al., “PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism,” Journal of Bone and Mineral Research, vol. 26, no. 11, pp. 2727–2736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Mannstadt, B. L. Clarke, T. Vokes et al., “Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study,” The Lancet Diabetes & Endocrinology, vol. 1, no. 4, pp. 275–283, 2013. View at Publisher · View at Google Scholar
  31. M. E. Cupp, S. K. Nayak, A. S. Adem, and W. J. Thomsen, “Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathwayss,” Journal of Pharmacology and Experimental Therapeutics, vol. 345, no. 3, pp. 404–418, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Sikjaer, L. Rejnmark, and L. Mosekilde, “PTH treatment in hypoparathyroidism,” Current Drug Safety, vol. 6, no. 2, pp. 89–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. N. E. Cusano, M. R. Rubin, D. J. McMahon et al., “Therapy of hypoparathyroidism with PTH(1–84): a prospective four-year investigation of efficacy and safety,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 1, pp. 137–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Y. Nottestad, J. J. Baumel, D. B. Kimmel, R. R. Recker, and R. P. Heaney, “The proportion of trabecular bone in human vertebrae,” Journal of Bone and Mineral Research, vol. 2, no. 3, pp. 221–229, 1987. View at Scopus
  35. R. R. Recker, S. P. Bare, S. Y. Smith et al., “Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1–84,” Bone, vol. 44, no. 1, pp. 113–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. N. E. Cusano, M. R. Rubin, D. J. McMahon et al., “The effect of PTH(1-84) on quality of life in hypoparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 6, pp. 2356–2361, 2013. View at Publisher · View at Google Scholar · View at Scopus